215 related articles for article (PubMed ID: 8040892)
21. Hyperthermia, thermotolerance and topoisomerase II inhibitors.
Kampinga HH
Br J Cancer; 1995 Aug; 72(2):333-8. PubMed ID: 7640214
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
23. The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties.
Lemke K; Poindessous V; Skladanowski A; Larsen AK
Mol Pharmacol; 2004 Oct; 66(4):1035-42. PubMed ID: 15258255
[TBL] [Abstract][Full Text] [Related]
24. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage.
Capranico G; Palumbo M; Tinelli S; Mabilia M; Pozzan A; Zunino F
J Mol Biol; 1994 Jan; 235(4):1218-30. PubMed ID: 8308885
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S
J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113
[TBL] [Abstract][Full Text] [Related]
26. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Med Res Rev; 2016 Mar; 36(2):248-99. PubMed ID: 26286294
[TBL] [Abstract][Full Text] [Related]
28. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.
Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK
Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066
[TBL] [Abstract][Full Text] [Related]
29. Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.
Campbell KJ; O'Shea JM; Perkins ND
BMC Cancer; 2006 Apr; 6():101. PubMed ID: 16630341
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones.
Routier S; Bernier JL; Catteau JP; Riou JF; Bailly C
Anticancer Drug Des; 1998 Jul; 13(5):407-15. PubMed ID: 9702207
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors.
Larsson R; Nygren P
Cancer; 1994 Nov; 74(10):2857-62. PubMed ID: 7954248
[TBL] [Abstract][Full Text] [Related]
33. DNA-topoisomerase inhibitors.
D'Incalci M
Curr Opin Oncol; 1993 Nov; 5(6):1023-8. PubMed ID: 8305535
[TBL] [Abstract][Full Text] [Related]
34. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors.
Skladanowski A; Plisov SY; Konopa J; Larsen AK
Mol Pharmacol; 1996 May; 49(5):772-80. PubMed ID: 8622625
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161).
Coughlin SA; Danz DW; Robinson RG; Klingbeil KM; Wentland MP; Corbett TH; Waud WR; Zwelling LA; Altschuler E; Bales E
Biochem Pharmacol; 1995 Jun; 50(1):111-22. PubMed ID: 7605336
[TBL] [Abstract][Full Text] [Related]
37. Mitoxantrone affects topoisomerase activities in human breast cancer cells.
Crespi MD; Ivanier SE; Genovese J; Baldi A
Biochem Biophys Res Commun; 1986 Apr; 136(2):521-8. PubMed ID: 3010982
[TBL] [Abstract][Full Text] [Related]
38. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
Hasinoff BB; Tran KT
J Inorg Biochem; 1999; 77(3-4):257-9. PubMed ID: 10643663
[TBL] [Abstract][Full Text] [Related]
39. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
[TBL] [Abstract][Full Text] [Related]
40. Biochemical pharmacology of anthracenediones and anthrapyrazoles.
Fry DW
Pharmacol Ther; 1991 Oct; 52(1):109-25. PubMed ID: 1666677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
